Skip to main content
2023 Guide to Patient Support Services


2023 PSS Guide

Viatris Advocate Patient Support Services


Viatris offers the Viatris Advocate program to provide continuous access and support to patients who have been prescribed Fulphila or Ogivri (Table).

Viatris Advocate

Viatris Advocate can help overcome the barriers that may stand between your patients and their treatment. Experienced and caring patient access specialists can assist with enrollment in the Co-pay Assistance Program and the Patient Assistance Program.

Co-pay Assistance Program

With Viatris Advocate, commercially insured patients may be able to access Fulphila for as little as $0 copay up to a maximum of $10,000 per 12-month period and Ogivri for as little as $0 copay up to a maximum of $25,000 per 12-month period. Patients may be eligible if they:

  • Are 18 years of age or older
  • Are residents of the United States or Puerto Rico
  • Have commercial prescription drug insurance
  • Do not participate in Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, or other similar federal or state programs.

Patient Assistance Program

Patients without insurance coverage for Fulphila or Ogivri who cannot afford their medication may be able to receive their medication free of charge. Eligibility requirements apply based on residency, income, and other factors. Contact Viatris Advocate at 833-695-2623 for more information.

TABLE Viatris Biosimilar Oncology Drugs

Patient support programs

Fulphila© (pegfilgrastim-jmdb)
Patient support programs

Ogivri© (trastuzumab-dkst) Injection 420 mg, 150 mg
Patient support programs

Fulphila© (pegfilgrastim-jmdb) Injection Indications

To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia

Ogivri© (trastuzumab-dkst) Injection Indications

Adjuvant treatment of HER2-overexpressing node-positive or nodenegative breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multimodality anthracycline-based therapy; in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer, or as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease; in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"